ELABELA/APELA Levels Are Not Decreased in the Maternal Circulation or Placenta among Women with Preeclampsia
Natasha Pritchard, Tu'uhevaha J Kaitu'u-Lino, Sungsam Gong, Justyna Dopierala, Gordon CS Smith, D Stephen Charnock-Jones, Stephen Tong
AMERICAN JOURNAL OF PATHOLOGY | ELSEVIER SCIENCE INC | Published : 2018
The genetic deletion of apelin receptor early endogenous ligand (Elabela; official name APELA) produces a preeclampsia-like phenotype in mice. However, evidence linking ELABELA with human disease is lacking. Therefore, we measured placental mRNA and circulating ELABELA in human samples. ELABELA mRNA (measured by RNA sequencing) was unchanged in 82 preeclamptic placentas compared with 82 matched controls (mean difference, 0.53%; 95% CI, -25.9 to 27.0; P = 0.78). We measured circulating ELABELA in 32 women with preterm preeclampsia (delivered at <34 weeks' gestation) and 32 matched controls sampled at the same gestational age. There was no difference in circulating ELABELA concentrations in th..View full abstract
Related Projects (3)
IDENTIFICATION OF WHICH FETAL GROWTH CHARTS AND BIRTHWEIGHT CENTILES ARE BEST ABLE TO IDENTIFY INFANTS AND MOTHERS AT RISK OF ADVERSE OBSTETRIC AND PERINATAL OUTCOMES
Preeclampsia, one of the most serious complications of pregnancy, affects around 3-8% of all pregnancies. Sadly, there is no treatment. We h..
Awarded by National Health and Medical Research Council of Australia
Awarded by National Institute for Health Research Cambridge Comprehensive Biomedical Research Center (Women's Health Theme) from the Medical Research Council (United Kingdom)
Supported by National Health and Medical Research Council of Australia grants 1062418 (T.J.K.-L.) and 1136418 (S.T.), and by postgraduate scholarship 1150828 from the National Health and Medical Research Council of Australia (N.P.). Some of the work described was supported by the National Institute for Health Research Cambridge Comprehensive Biomedical Research Center (Women's Health Theme), project grant G1100221 from the Medical Research Council (United Kingdom), and the Stillbirth and Neonatal Death Society (Sands). This study also was supported by GE Healthcare (donation of 2 Voluson i Ultrasound Systems) and by the National Institute for Health Research Cambridge Clinical Research Facility, where research visits took place.